6XV0 image
Entry Detail
PDB ID:
6XV0
Title:
lauric acid functionalized hexamolybdoaluminate bound to human serum albumin
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2020-01-21
Release Date:
2020-03-18
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.31
R-Value Work:
0.26
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Serum albumin
Chain IDs:A
Chain Length:585
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Binding of a Fatty Acid-Functionalized Anderson-Type Polyoxometalate to Human Serum Albumin.
Inorg.Chem. 59 5243 5246 (2020)
PMID: 32255347 DOI: 10.1021/acs.inorgchem.9b03407

Abstact

The Anderson-type hexamolybdoaluminate functionalized with lauric acid (LA), (TBA)3[Al(OH)3Mo6O18{(OCH2)3CNHCOC11H23}]·9H2O (TBA-AlMo6-LA, where TBA = tetrabutylammonium), was prepared via two synthetic routes and characterized by thermogravimetric and elemental analyses, mass spectrometry, IR and 1H NMR spectroscopy, and powder and single-crystal X-ray diffraction. The interaction of TBA-AlMo6-LA with human serum albumin (HSA) was investigated via fluorescence and circular dichroism spectroscopy. The results revealed that TBA-AlMo6-LA binds strongly to HSA (63% quenching at an HSA/TBA-AlMo6-LA ratio of 1:1), exhibiting static quenching. In contrast to TBA-AlMo6-LA, the nonfunctionalized polyoxometalate, Na3(H2O)6[Al(OH)6Mo6O18]·2H2O (AlMo6), showed weak binding toward HSA (22% quenching at a HSA/AlMo6 ratio of 1:25). HSA binding was confirmed by X-ray structure analysis of the HSA-Myr-AlMo6-LA complex (Myr = myristate). These results provide a promising lead for the design of novel polyoxometalate-based hybrids that are able to exploit HSA as a delivery vehicle to improve their pharmacokinetics and bioactivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures